Zev Allison
Cardiovascular Disease · Torrance, CANPI 1952930513
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.
Across 87 payments — averaging $48.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AOP Health US, LLC$839
- Abiomed$642
- Shockwave Medical, Inc$367
- Heartflow, Inc.$339
- Edwards Lifesciences$295
- Scpharmaceuticals Inc.$229
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$1504%
- Food & beverage$4,01994%
- Gifts$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AOP Health US, LLC | 2 | $839 |
| Abiomed | 9 | $642 |
| Shockwave Medical, Inc | 15 | $367 |
| Heartflow, Inc. | 7 | $339 |
| Edwards Lifesciences | 2 | $295 |
| Scpharmaceuticals Inc. | 6 | $229 |
| Boston Scientific | 2 | $227 |
| Pfizer | 10 | $209 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $203 |
| Novartis | 6 | $158 |
| Eko Health, Inc. | 1 | $150 |
| Regeneron Healthcare Solutions, Inc. | 3 | $111 |
| AstraZeneca | 4 | $92 |
| Merck | 3 | $77 |
| Johnson & Johnson | 2 | $57 |
| Lexicon Pharmaceuticals, Inc. | 2 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $49 |
| Bayer | 1 | $32 |
| Invivyd Inc | 1 | $31 |
| Terumo Medical Corporation | 1 | $29 |
| Altathera Pharmaceuticals LLC | 1 | $28 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,255 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 31 | $455 |
| Rosuvastatin Calcium | 13 | $451 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $289 |
| Losartan Potassium | 18 | $284 |
| Atorvastatin Calcium | 11 | $144 |
| Amlodipine Besylate | 22 | $112 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Torrance
- Matthew BudoffTorrance$3.6M
- Ronald OudizTorrance$617K
- William FrenchTorrance$161K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.